Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans

Abhinav Kumar; Elif Melis Bicer; Paul Pfeffer; Marco P Monopoli; Kenneth A Dawson; Jonny Eriksson; Katarina Edwards; Steven Lynham; Matthew Arno; Annelie F Behndig; Anders Blomberg; Graham Somers; Dave Hassall; Lea Ann Dailey; Ben Forbes; Ian Mudway

doi:10.1016/j.nano.2017.06.008

Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans

Abhinav Kumar, Elif Melis Bicer, Paul Pfeffer, Marco P Monopoli, Kenneth A Dawson, Jonny Eriksson, Katarina Edwards, Steven Lynham, Matthew Arno, Annelie F Behndig, Anders Blomberg, Graham Somers, Dave Hassall, Lea Ann Dailey, Ben Forbes, Ian Mudway

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

338 Downloads (Pure)

Abstract

Most inhaled nanomedicines in development are for the treatment of lung disease, yet little is known about their interaction with the respiratory tract lining fluids (RTLF). Here we combined the use of nano-silica, as a protein concentrator, with label-free snapshot proteomics (LC-MS/MS; key findings confirmed by ELISA) to generate a quantitative profile of the RTLF proteome and provided insight into the evolved corona; information that may be used in future to improve drug targeting to the lungs by inhaled medicines.

The asthmatic coronal proteome displayed a reduced contribution of surfactant proteins (SP-A and B) and a higher contribution of α1-antitrypsin. Pathway analysis suggested that asthmatic RTLFs may also be deficient in proteins related to metal handling (e.g. lactoferrin). This study demonstrates how the composition of the corona acquired by inhaled nanoparticles is modified in asthma and suggests depressed mucosal immunity even in mild airway disease.

Original language	English
Pages (from-to)	2517-2521
Journal	Nanomedicine-Nanotechnology Biology And Medicine
Volume	13
Issue number	8
Early online date	22 Jun 2017
DOIs	https://doi.org/10.1016/j.nano.2017.06.008
Publication status	E-pub ahead of print - 22 Jun 2017

Access to Document

10.1016/j.nano.2017.06.008

Differences in the coronal_KUMAR_Publishedonline22June2017_GREEN AAM (CC BY-NC-ND)Accepted author manuscript, 728 KBLicence: CC BY-NC-ND

Cite this

Kumar, A., Bicer, E. M., Pfeffer, P., Monopoli, M. P., Dawson, K. A., Eriksson, J., Edwards, K., Lynham, S., Arno, M., Behndig, A. F., Blomberg, A., Somers, G., Hassall, D., Dailey, L. A., Forbes, B., & Mudway, I. (2017). Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans. Nanomedicine-Nanotechnology Biology And Medicine, 13(8), 2517-2521. Advance online publication. https://doi.org/10.1016/j.nano.2017.06.008

@article{3b13b5b134134aa1bbd9acaf727938b8,

title = "Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans",

abstract = "Most inhaled nanomedicines in development are for the treatment of lung disease, yet little is known about their interaction with the respiratory tract lining fluids (RTLF). Here we combined the use of nano-silica, as a protein concentrator, with label-free snapshot proteomics (LC-MS/MS; key findings confirmed by ELISA) to generate a quantitative profile of the RTLF proteome and provided insight into the evolved corona; information that may be used in future to improve drug targeting to the lungs by inhaled medicines. The asthmatic coronal proteome displayed a reduced contribution of surfactant proteins (SP-A and B) and a higher contribution of α1-antitrypsin. Pathway analysis suggested that asthmatic RTLFs may also be deficient in proteins related to metal handling (e.g. lactoferrin). This study demonstrates how the composition of the corona acquired by inhaled nanoparticles is modified in asthma and suggests depressed mucosal immunity even in mild airway disease.",

author = "Abhinav Kumar and Bicer, {Elif Melis} and Paul Pfeffer and Monopoli, {Marco P} and Dawson, {Kenneth A} and Jonny Eriksson and Katarina Edwards and Steven Lynham and Matthew Arno and Behndig, {Annelie F} and Anders Blomberg and Graham Somers and Dave Hassall and Dailey, {Lea Ann} and Ben Forbes and Ian Mudway",

year = "2017",

month = jun,

day = "22",

doi = "10.1016/j.nano.2017.06.008",

language = "English",

volume = "13",

pages = "2517--2521",

journal = "Nanomedicine-Nanotechnology Biology And Medicine",

issn = "1549-9634",

publisher = "Elsevier",

number = "8",

}

Kumar, A , Bicer, EM , Pfeffer, P, Monopoli, MP, Dawson, KA, Eriksson, J, Edwards, K, Lynham, S , Arno, M, Behndig, AF, Blomberg, A, Somers, G, Hassall, D, Dailey, LA , Forbes, B & Mudway, I 2017, 'Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans', Nanomedicine-Nanotechnology Biology And Medicine, vol. 13, no. 8, pp. 2517-2521. https://doi.org/10.1016/j.nano.2017.06.008

TY - JOUR

T1 - Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans

AU - Kumar, Abhinav

AU - Bicer, Elif Melis

AU - Pfeffer, Paul

AU - Monopoli, Marco P

AU - Dawson, Kenneth A

AU - Eriksson, Jonny

AU - Edwards, Katarina

AU - Lynham, Steven

AU - Arno, Matthew

AU - Behndig, Annelie F

AU - Blomberg, Anders

AU - Somers, Graham

AU - Hassall, Dave

AU - Dailey, Lea Ann

AU - Forbes, Ben

AU - Mudway, Ian

PY - 2017/6/22

Y1 - 2017/6/22

N2 - Most inhaled nanomedicines in development are for the treatment of lung disease, yet little is known about their interaction with the respiratory tract lining fluids (RTLF). Here we combined the use of nano-silica, as a protein concentrator, with label-free snapshot proteomics (LC-MS/MS; key findings confirmed by ELISA) to generate a quantitative profile of the RTLF proteome and provided insight into the evolved corona; information that may be used in future to improve drug targeting to the lungs by inhaled medicines. The asthmatic coronal proteome displayed a reduced contribution of surfactant proteins (SP-A and B) and a higher contribution of α1-antitrypsin. Pathway analysis suggested that asthmatic RTLFs may also be deficient in proteins related to metal handling (e.g. lactoferrin). This study demonstrates how the composition of the corona acquired by inhaled nanoparticles is modified in asthma and suggests depressed mucosal immunity even in mild airway disease.

AB - Most inhaled nanomedicines in development are for the treatment of lung disease, yet little is known about their interaction with the respiratory tract lining fluids (RTLF). Here we combined the use of nano-silica, as a protein concentrator, with label-free snapshot proteomics (LC-MS/MS; key findings confirmed by ELISA) to generate a quantitative profile of the RTLF proteome and provided insight into the evolved corona; information that may be used in future to improve drug targeting to the lungs by inhaled medicines. The asthmatic coronal proteome displayed a reduced contribution of surfactant proteins (SP-A and B) and a higher contribution of α1-antitrypsin. Pathway analysis suggested that asthmatic RTLFs may also be deficient in proteins related to metal handling (e.g. lactoferrin). This study demonstrates how the composition of the corona acquired by inhaled nanoparticles is modified in asthma and suggests depressed mucosal immunity even in mild airway disease.

U2 - 10.1016/j.nano.2017.06.008

DO - 10.1016/j.nano.2017.06.008

M3 - Article

SN - 1549-9634

VL - 13

SP - 2517

EP - 2521

JO - Nanomedicine-Nanotechnology Biology And Medicine

JF - Nanomedicine-Nanotechnology Biology And Medicine

IS - 8

ER -

Differences in the coronal proteome acquired by particles depositing in the lungs of asthmatic versus healthy humans

Abstract

Access to Document

Fingerprint

Cite this